Meeting
2023 ASCO Annual Meeting
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).
Authors
Amer Methqal Zeidan
Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT
Amer Methqal Zeidan , Leyla Hernandez Donoso , Sejla Hodzic , Henry F Owusu , Dhrubajyoti Pathak , Summera Qiheng Zhou , Eytan Stein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7044)
DOI
10.1200/JCO.2023.41.16_suppl.7044
Abstract #
7044
Poster Bd #
174
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.
First Author: Farhad Ravandi
Poster
2017 ASCO Annual Meeting
Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.
First Author: Koichi Takahashi
Poster
2024 ASCO Annual Meeting
Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).
First Author: Alma Habib
Poster
2023 ASCO Annual Meeting
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.
First Author: Maha AT Elsebaie